Skip to main content

COMPASS Pathways PLC (CMPS)

NASDAQ: CMPS · IEX Real-Time Price · USD
32.25 -0.37 (-1.13%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap1.38B
Revenue (ttm)n/a
Net Income (ttm)-65.74M
Shares Out41.70M
EPS (ttm)-2.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume161,220
Open32.28
Previous Close32.62
Day's Range31.90 - 33.10
52-Week Range29.31 - 61.69
Betan/a
AnalystsStrong Buy
Price Target72.11 (+123.6%)
Est. Earnings DateNov 11, 2021

About CMPS

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.

IndustryHealth Care Providers & Services
IPO DateSep 18, 2020
Employees61
Stock ExchangeNASDAQ
Ticker SymbolCMPS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price forecast is 72.11, which is an increase of 123.60% from the latest price.

Price Target
$72.11
(123.60% upside)
Analyst Consensus: Strong Buy

News

1 Recent Healthcare IPO to Put on Your Radar

Here's a pharmaceutical company that could have an incredibly bright future.

1 day ago - The Motley Fool

COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences

London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, a...

4 days ago - GlobeNewsWire

Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?

Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.

4 days ago - Zacks Investment Research

Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0

Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances. C...

1 week ago - Benzinga

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an in...

1 week ago - GlobeNewsWire

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, the res...

2 weeks ago - GlobeNewsWire

COMPASS Pathways to participate in Citi, Morgan Stanley and HC Wainwright investor conferences in September

London, UK – 7 September 2021, Sept. 07, 2021 (GLOBE NEWSWIRE) -- London, UK – 7 September 2021           COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating pati...

2 weeks ago - GlobeNewsWire

3 Biotech Stocks Wall Street Expects to Double Soon

All three stocks on this list can more than double your money according to investment bank analysts who cover them.

Other symbols:AXSMZGNX
2 weeks ago - The Motley Fool

Open-Minded? Buy This Game-Changing Psychedelics Stock Now

Excellent investing opportunities frequently seem outlandish.

4 weeks ago - The Motley Fool

Are Options Traders Betting on a Big Move in COMPASS Pathways (CMPS) Stock?

Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge

They're the first pioneers in exciting new markets.

Other symbols:ATAITALK
1 month ago - The Motley Fool

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

LONDON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

1 month ago - GlobeNewsWire

Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022

By 2030, psychedelic therapy will be the gold standard for mental health treatment. And Compass is at the forefront of commercialization.

1 month ago - InvestorPlace

COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021

London, UK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, an...

1 month ago - GlobeNewsWire

COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences

COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences

1 month ago - GlobeNewsWire

7 Stocks to Buy if You Think Alternative Therapies Are the Future

Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments. The post 7 Stocks to Buy if You Think Alternative Therapies Are the Futur...

Other symbols:GTBIFMNMDSTIM
1 month ago - InvestorPlace

Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training

London, UK – 21 July 2021         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, an...

2 months ago - GlobeNewsWire

Is It Too Early to Invest in Psychedelic Stocks?

Legislation is starting to open up the industry but investors who are hoping to cash in on its growth opportunities could be waiting a very long time.

2 months ago - The Motley Fool

COMPASS Pathways to participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit

London, UK, July 07, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, an...

2 months ago - GlobeNewsWire

3 Top Psychedelic Stocks to Buy Now

These companies developing hallucinogens have more than meets the eye.

Other symbols:MNMD
2 months ago - The Motley Fool

Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study

Compass Pathways (NASDAQ:CMPS), a biotech company in the psychedelics space, announced it has completed a key milestone on its path to obtaining FDA approval for psilocybin in the treatment of depressio...

2 months ago - Benzinga

Pandemic Fallout: 6 Mental Health Stocks To Watch

One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people's mental health. The next global health crisis may be related to mental health issues such a...

Other symbols:ACHCITCILFSTMNMDTDOC
2 months ago - Benzinga

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psiloc...

COMPASS on track to report data in late 2021 COMPASS on track to report data in late 2021

2 months ago - GlobeNewsWire